1352 related articles for article (PubMed ID: 21884771)
21. Particle design of poorly water-soluble drug substances using supercritical fluid technologies.
Yasuji T; Takeuchi H; Kawashima Y
Adv Drug Deliv Rev; 2008 Feb; 60(3):388-98. PubMed ID: 18068261
[TBL] [Abstract][Full Text] [Related]
22. Application of a ternary HP-β-CD-complex approach to improve the dissolution performance of a poorly soluble weak acid under biorelevant conditions.
Zoeller T; Dressman JB; Klein S
Int J Pharm; 2012 Jul; 430(1-2):176-83. PubMed ID: 22531855
[TBL] [Abstract][Full Text] [Related]
23. Formulation of poorly water-soluble Gemfibrozil applying power ultrasound.
Ambrus R; Naghipour Amirzadi N; Aigner Z; Szabó-Révész P
Ultrason Sonochem; 2012 Mar; 19(2):286-91. PubMed ID: 21835674
[TBL] [Abstract][Full Text] [Related]
24. The utility of cyclodextrins for enhancing oral bioavailability.
Carrier RL; Miller LA; Ahmed I
J Control Release; 2007 Nov; 123(2):78-99. PubMed ID: 17888540
[TBL] [Abstract][Full Text] [Related]
25. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
Lindenberg M; Kopp S; Dressman JB
Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
[TBL] [Abstract][Full Text] [Related]
26. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs.
Müllertz A; Ogbonna A; Ren S; Rades T
J Pharm Pharmacol; 2010 Nov; 62(11):1622-36. PubMed ID: 21039546
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
[TBL] [Abstract][Full Text] [Related]
28. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.
Merisko-Liversidge E; Liversidge GG
Adv Drug Deliv Rev; 2011 May; 63(6):427-40. PubMed ID: 21223990
[TBL] [Abstract][Full Text] [Related]
29. Liquisolid systems and aspects influencing their research and development.
Vraníková B; Gajdziok J
Acta Pharm; 2013 Dec; 63(4):447-65. PubMed ID: 24451071
[TBL] [Abstract][Full Text] [Related]
30. Drug nanoparticles: formulating poorly water-soluble compounds.
Merisko-Liversidge EM; Liversidge GG
Toxicol Pathol; 2008 Jan; 36(1):43-8. PubMed ID: 18337220
[TBL] [Abstract][Full Text] [Related]
31. Developing early formulations: practice and perspective.
Li P; Zhao L
Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
[TBL] [Abstract][Full Text] [Related]
32. Dissolution-modulating mechanism of pH modifiers in solid dispersion containing weakly acidic or basic drugs with poor water solubility.
Tran PH; Tran TT; Lee KH; Kim DJ; Lee BJ
Expert Opin Drug Deliv; 2010 May; 7(5):647-61. PubMed ID: 20205605
[TBL] [Abstract][Full Text] [Related]
33. Lipid-based formulations for oral administration of poorly water-soluble drugs.
Mu H; Holm R; Müllertz A
Int J Pharm; 2013 Aug; 453(1):215-24. PubMed ID: 23578826
[TBL] [Abstract][Full Text] [Related]
34. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
[TBL] [Abstract][Full Text] [Related]
35. In vitro Methods for In vitro-In vivo Correlation (IVIVC) for Poorly Water Soluble Drugs: Lipid Based Formulation Perspective.
Kazi M; Al Amri R; Alanazi FK; Hussain MD
Curr Drug Deliv; 2018; 15(7):918-929. PubMed ID: 29336263
[TBL] [Abstract][Full Text] [Related]
36. Increasing the cyclodextrin complexation of drugs and drug biovailability through addition of water-soluble polymers.
Loftsson T
Pharmazie; 1998 Nov; 53(11):733-40. PubMed ID: 9853355
[TBL] [Abstract][Full Text] [Related]
37. Current Trends in Self-Emulsifying Drug Delivery Systems (SEDDSs) to Enhance the Bioavailability of Poorly Water-Soluble Drugs.
Karwal R; Garg T; Rath G; Markandeywar TS
Crit Rev Ther Drug Carrier Syst; 2016; 33(1):1-39. PubMed ID: 27279337
[TBL] [Abstract][Full Text] [Related]
38. New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin.
Taupitz T; Dressman JB; Klein S
Eur J Pharm Biopharm; 2013 May; 84(1):208-18. PubMed ID: 23246797
[TBL] [Abstract][Full Text] [Related]
39. Degrees of order: A comparison of nanocrystal and amorphous solids for poorly soluble drugs.
Peltonen L; Strachan CJ
Int J Pharm; 2020 Aug; 586():119492. PubMed ID: 32505579
[TBL] [Abstract][Full Text] [Related]
40. Enhancing the solubility and bioavailability of poorly water-soluble drugs using supercritical antisolvent (SAS) process.
Abuzar SM; Hyun SM; Kim JH; Park HJ; Kim MS; Park JS; Hwang SJ
Int J Pharm; 2018 Mar; 538(1-2):1-13. PubMed ID: 29278733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
